Venous thromboembolism is an important cause of postoperative morbidity and mortality in bariatric surgery. Studies of direct oral anticoagulants (DOACs) are not available in this surgical field. The objective of this phase 1 clinical trial was to investigate pharmacokinetic and pharmacodynamic (PK/PD) parameters of rivaroxaban in bariatric patients.
Introduction
The prevalence of obesity as well as morbid obesity is increasing worldwide and therefore becoming a growing medical and socioeconomic burden [3] [4] [5] . Bariatric surgery leads to the most sustained reduction of weight and associated comorbidities, but patients undergoing bariatric surgery are at increased risk of venous thromboembolic events (VTE) [6] . Obesity is an independent risk factor for the development of venous thromboembolism itself and the association between obesity and VTE after bariatric surgery is well established [7] [8] [9] . The incidence of symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE) ranges from 0 to 5.4% and 0 to 6.4%, respectively, but the true incidence remains uncertain [10] . Although the overall incidence is low, VTE represents a significant cause of morbidity and mortality after surgery. Even with aggressive prophylaxis, VTE cannot be fully prevented [11] [12] [13] . The American Society of Metabolic and Bariatric Surgeons and the American College of Chest Physicians recommend prophylaxis against DVT for all bariatric surgery patients [14] . Routine prophylactic perioperative use of low-molecular weight heparins (LMWHs), intermittent pneumatic compression devices and early mobilization are currently the major accepted measures to prevent VTE, particularly in high-risk groups [body mass index (BMI) >50 kg/m 2 ], advanced age, history of previous VTE, obesity hypoventilation syndrome, open and revisional surgery [13, 15] . In clinical practice, physicians lack guidelines supporting their therapeutic decisions regarding LMWH dosing in the field of bariatric surgery. In summary, there exists currently no robust evidence to provide guidance regarding type, dose and duration of antithrombotic prophylaxis after bariatric surgery [15] . Due to the fact that most postdischarge VTE events occur within the first 30 days after surgery, extended VTE prophylaxis should be considered, but the specific duration of chemical prophylaxis is still a matter of discussion [12] . Direct oral anticoagulants (DOACs) are a new class of anticoagulants, whose application is more convenient compared to LMWH. DOACs allow effective and safe anticoagulation and their monitoring is usually not required.
Rivaroxaban is the first oral direct factor Xa inhibitor marketed. It was initially approved for the prevention of venous thromboembolism in patients after elective hip and knee replacement surgery. Rivaroxaban is generally well tolerated and demonstrates a predictable, dose-dependent pharmacology profile up to 24 h after single dose application. The 10 mg dose of rivaroxaban has a high oral bioavailability (80-100%) irrespective of food intake, a rapid onset of action and the maximum plasma level is achieved 2-4 h after oral administration [16, 17] . Prophylaxis with rivaroxaban had a significantly higher efficacy in VTE prophylaxis as compared with enoxaparin after hip and knee replacement surgery with similar rates of bleeding [18] [19] [20] [21] . Friedman et al. [22] compared the efficacy of rivaroxaban in orthopaedic surgery patients with BMI ≥40 kg/m 2 vs. <40 kg/m 2 (posthoc subanalysis of a group of 12 355 patients) and found no difference in the incidence rates of DVT, PE or bleedings. Since age, sex or body weight [23] do not seem to alter pharmacokinetics (PK) and pharmacodynamics (PD) to a clinically relevant degree, the current recommendation for prophylaxis is 10 mg rivaroxaban once daily in all patients. However, as pointed out in an editorial by Duffull [24] , rivaroxaban PK/PD studies indicate a high degree of between-subject variability in the drug concentration-time profile [23] . Additionally, the effects of bariatric surgery on PK and PD parameters of DAOCs have not been sufficiently investigated to date, and there is no approved dosing recommendation for obese patient in the perioperative setting. With this clinical trial, we close part of this knowledge gap and lay ground for a broader investigation of rivaroxaban in morbidly obese patients, especially in the perioperative setting.
Methods
This single centre open-label, nonrandomized phase 1 clinical trial was designed to investigate the single dose PK and PD parameters of rivaroxaban when administered to 12 patients undergoing a planned bariatric surgical procedure [six Roux-en-Y gastric bypass (RYGB) and six sleeve gastrectomy (SG) patients] in the framework of a pilot study.
The trial was approved by the Independent Ethics Committee of Bern, Switzerland, and the Swiss competent authority, Swissmedic. All patients gave written informed consent, and the trial was conducted according to the Declaration of Helsinki, the Good Clinical Practice guideline and local laws and regulations. The study was registered in the ClinicalTrials.gov registry with the identifier number NCT02438098.
Inclusion and exclusion criteria
Eligible patients were men and women, aged 18 years or older, with a BMI ≥35 kg/m 2 with planned elective primary laparoscopic bariatric surgery (RYGB or SG). Main exclusion criteria were a history of active bleeding or a high-risk for bleeding, a clinical indication for long-term anticoagulation, and evidence of a thrombosis or PE in the personal history. The decision to perform bariatric surgery was taken independent of this trial.
Study procedure
Enrolled patients received a single oral dose of 10 mg rivaroxaban (Xarelto; Bayer Pharma AG, Germany) 1 day prior to and 3 days after surgery under nonfasting conditions. Venous blood samples were taken to assess the PK and PD parameters on both of these days. 
Study endpoints
Primary study endpoints were the single dose PK parameters of rivaroxaban after oral administration prior to and after RYGB and SG. Secondary endpoints were PD parameters as assessed by thrombin-antithrombin complexes (TAT), Prothrombin fragments 1 and 2 (F1 + 2) and D-dimers. Safety endpoints were mortality, clinically evident proximal or distal DVT, PE and all bleeding events.
Sample analysis
Anti-Xa activity of heparins and rivaroxaban was measured using the CE labelled chromogenic anti-FXa assay Biophen Heparin 6 (Hyphen BioMed, Neuilly-sur Oise, France). This is a one-stage assay that utilizes endogenous antithrombin. It is an automated kinetic method during which a constant amount of exogenously added bovine FXa is inhibited by anticoagulants in the sample to be tested. Noninhibited FXa cleaves a FXa-specific chromogenic substrate, producing a yellow signal that is detected at 405 nm. The measured antiXa activity was converted to units anti-Xa ml -1 (LMWH) or ng ml -1 (rivaroxaban) by the appropriate commercial calibrators, respectively. As for rivaroxaban, the performance of this assay has been evaluated against the standard highperformance liquid chromatography with mass spectrometry method and results were comparable [25] . Prothrombin time was measured using Innovin (Siemens, Marburg, Germany) as the reagent, the assay was calibrated with a commercial kit containing four defined lyophilized plasmas (Siemens), the results are the average of duplicate measurements. Activated partial thromboplastin time is measured with Pathromtin SL (Siemens), the results are the average of duplicate measurements. Coagulation and chromogenic assays were performed on a Behring Coagulation System and a CS-5100 automated analyser (Siemens), respectively [26] .
Prothrombin activation fragments 1 + 2 (F1+2) and TAT were measured by a quantitative sandwich enzyme immunoassay, according to the protocol of the manufacturers (Enzygnost TAT micro and Enzygnost F1+2 micro; Siemens). The absorbance was measured using a microtiter plate reader at 492 nm [27] . D-dimers concentrations were determined by an automated quantitative immunoassay, according to the manufacturer's instructions (INNOVANCE D-dimer; Siemens).
Safety and tolerability
Prior to the application of the study drug, every patient received an extensive evaluation including clinical chemistry, haematology and coagulation analyses, an electrocardiogram and clinical workup. After the application of the study medication, safety and tolerability were closely monitored during the first 24 h by measuring vital signs and specifically asking for untoward symptoms. Adverse events were monitored throughout the study to the final visit at 30 (±7) days postoperation. Each adverse event was classified according to its severity and seriousness.
Statistics
Demographics and relevant baseline variables are summarized for the per protocol set in tabular form. Data are stratified by type of surgery (RYGB, SG). Categorical data are presented as frequencies and percentages. For continuous variables, total number of measurements, mean and standard deviation are presented. Per protocol, only descriptive statistical analyses were foreseen.
PK and PD analysis
PK parameters were assessed prior to and after surgery by measuring rivaroxaban concentrations at nine different time points: prior to administration of study medication and 1, 2, 3, 4, 6, 8, 12 and 24 h thereafter. Noncompartmental PK parameters have been calculated using the R package For both surgical procedures, the following PK endpoints are presented: AUC; C max : peak plasma concentration; t 1/2 : terminal half-life; V z/f : = (Dose/C 0 )/bodyweight: apparent volume of distribution during the terminal phase divided by total body weight (in kg); t max : time to peak plasma concentration. For some patients t max could not be determined, since its values were the same for two points of time. These measurements were not included in the analysis of t max . C max and t max are presented in tabular and graphical form.
For D-dimers, prothrombin fragments (F1+2) and TAT, maximal concentration C max and time to maximal concentration t max is presented in tabular form. Two patients (ID 7 prior to surgery and ID 12 after surgery) are only partially included in the analysis since no valid PD results were obtained due to technically difficult blood sampling. For the assessment of the PD parameters, measurements at the following points of time were used: 0, 1, 3, 12 and 24 h after the application of the study medication. PK/PD data were only generated and analysed if the patient in fact received the study treatment. 5 h) . However, the range was similar for both groups and both assessments (pre-and postbariatric). Half-life of rivaroxaban was similar in both groups prior to and after bariatric surgery (Table 1) . PK curves of the two different surgical procedures are displayed in Figure 1 . PK parameters are summarized in Table 2 .
Results

Study population
PD
PD effects of rivaroxaban has been evaluated by the assessment of TAT, prothrombin fragments F1+2 and D-dimers. TAT decreased in the preoperative setting within the first 1-3 h after the application of rivaroxaban. Values significantly dropped within 1 h from a median TAT concentration of 10.6 to 2.6 ng ml -1 and from 13.7 to 2.8 ng ml -1 for the RYGB and the SG group, respectively, and this effect was maintained for at least 12 hours after the application of rivaroxaban. After 24 hours, TAT values increased slightly but were still lower than those values prior to the application of rivaroxaban for both groups in the preoperative setting ( Figure 2 , Figure S1 , Table S1 ). Postoperatively, TAT values were already decreased prior to the application of rivaroxaban, due to the fact that patients received prophylactic LMWH the day before as part of standard of care. However, a further slight decrease in these values was observed both 3 and 12 h after the application of rivaroxaban on Study Day 3. After 24 h, TAT values increased similar to the increase observed in the assessment taken prior to the surgical intervention (Figure 2 , Figure S1 , Table S1 ).
Similar to TAT, F1+2 are characterized by a relevant drop after the application of rivaroxaban. Decrease of concentration is most prominent 12 h after the application of rivaroxaban (reduction of median F1+2 concentration within 12 hours from 269 to 119 pmol l -1 and from 212
to 71 pmol l -1 for the RYGB and the SG group, respectively) whereas values rise towards the initial level after 24 h (Figure 3 , Figure S2 , Table S1 ). The dynamic changes observed with F1+2 was similar in the pre-and postoperative setting.
D-dimers decrease slightly during the first 12 hours after the application of rivaroxaban (reduction of median D-dimer concentrations from 708 to 657 and from 629 ng ml -1 to 572 ng ml -1 over 12 h for the RYGB and the SG group, respectively) and increase to the initial Ddimer level 24 h after the application of rivaroxaban. In the postoperative setting, D-dimer values are generally higher than in the preoperative assessment but the dynamic changes observed are comparable to the preoperative setting (Figure 4 , Figure S3 , Table S1 ). The PD parameters of two patients with SG (one patients in the presurgical and one in the postsurgical group) were excluded from further analysis due to false positive values that have been attributed to technical problems during the collection of the blood sample.
Safety and tolerability
All recorded adverse events and serious adverse events are listed in Table 3 together with the safety measures taken. There was only one serious adverse event. This patient suffered from a jejunal obstruction after RYGB that was unrelated to the study intervention but required surgical revision. This patient was withdrawn from the study and from the per protocol analysis set. Only in two events was the relationship to the study medication rated as possible, and both events were assessed as mild and moderate in intensity (Table 3) .
Discussion
Single doses of 10 mg rivaroxaban resulted in similar systemic exposures, as measured by AUC, both prior to and after bariatric surgery, regardless of the type of bariatric procedure performed. In contrast to what might have been expected, the AUC values of both surgical groups were higher in the postoperative setting, compared to the preoperative setting. Maximum concentrations (C max ) were higher in the SG group postoperatively and lower in the RYGB group compared to the presurgical assessment. However, this effect is less pronounced than what has been observed with different 10 mg galenic formulations of rivaroxaban and lies in the expected range of variation of other nonobese patient groups [17, 28] . In the postoperative setting of RYGB patients t max is slightly delayed, but the range remains unaffected. Overall, AUC of 10 mg rivaroxaban in this obese study population (prior to surgery 952.6 μg·h l -1 , after surgery 1095.5 μg·h l -1 ) was Table 2 Pharmacokinetic parameters for all patients (summarized), and Roux-en-Y gastric bypass as well as sleeve gastrectomy patients (separated); prior to and after surgery the geometric mean and the coefficient of variation is presented. For t max the median and the range is presented. The ratio prior to surgery/after surgery is presented together with its 95% confidence interval 
AUC, area under the plasma-concentration time curve from time 0 to infinity; C max , peak plasma concentration; t 1/2 , terminal half-life; V z/f , (Dose/C 0 )/ bodyweight apparent volume of distribution during the terminal phase divided by total body weight (in kg); t max , time to peak plasma concentration Figure 2 Thrombin-antithrombin complex concentrations (median and range); left Roux-en-Y Gastric bypass; n = 6; right, sleeve gastrectomy, n = 5
Rivaroxaban in bariatric surgery similar to the AUC in healthy individuals with normal BMI (1020/14.9 μg·h l -1 ) and patients after total hip replacement surgery (1170 μg·h l -1 ) that have been exposed to the same dose and formulation of rivaroxaban supporting the finding that the AUC is not affected in a significant way by bariatric surgery [17, 29] . Prophylactic doses of rivaroxaban administered prior to the bariatric surgery led to a rapid PD response with a significant (>70%) median decrease of TAT within 1 h after the exposition to the anticoagulant. In the postoperative groups the initial drop of TAT was less pronounced since the patients already received LMWH the day prior to the application of rivaroxaban as part of the standard prophylactic treatment. TAT levels 24 h after the exposition to rivaroxaban did not return to normal as compared to preoperative levels prior to the ingestion of rivaroxaban but to a range observed 1-3 h after the application of rivaroxaban.
Additionally, the PD effects as measured by prothrombin activation fragments is characterized by a significant (>55%) median drop of F1+2 value within the timeframe of 12 h. After 24 h, prothrombin activation fragments remained below the levels measured prior to the administration of rivaroxaban in the preoperative groups, whereas, in the postoperative group, F1+2 levels were equal to the levels measured prior to the administration of rivaroxaban, probably reflecting the effect of previously administered LMWH.
The delayed response of F1+2 compared to TAT is explained by its longer half-life (about 90 min) compared to TAT (about 10 min) [30] . For D-dimers, which are characterized by an even longer half-life (around 8-12 h), only a slight decrease of concentration could be observed 12 h after rivaroxaban ingestion.
With the exception of baseline levels of F1+2 and particularly TAT, PD values in the postsurgical analyses were higher compared to the presurgical investigations as a consequence of the procoagulant effect of the surgical intervention. This observation may indicate that the same dose of anticoagulant is slightly less effective in controlling the postoperatively increased procoagulant state.
Kubitza et al. [31] investigated PK, PD and the safety profile of 10 mg single dose rivaroxaban administration in different body weight groups. Interestingly, AUC values were probable explanation for this observation is the low volume of distribution of rivaroxaban. In fact, rivaroxaban is extensively bound to plasma proteins und has a relatively low tissue affinity [31] . In the trial of Kubitza et al. [31] , women in the ≤50 kg weight group showed an increased C max (178 μg l -1 ) whereas rivaroxaban AUCs were similar in all groups. Our results demonstrate a higher C max (170 μg l -1 ) and an increased interindividual variability of postoperative rivaroxaban plasma levels in the SG group but a slightly decreased C max (110 μ l -1 ) and an increased t max (plus 1 h, range unaffected) in the RYGB group, again with similar AUCs in both surgical groups prior to and after the bariatric intervention. Reasons for these observations may be an increased variability in gastric passage time in patients who had bariatric surgery directly affecting the stomach, and alterations in the site of drug absorption in RYGB patients as a consequence of the partially bypassed stomach and the bypassed duodenum. However, these observations are within the known variations of rivaroxaban PK parameters. Overall, prophylactic application of rivaroxaban in bariatric patients resulted in PK results comparable to those reported from prior trials and the assessment of PD parameters supports the clinical effectiveness of a 10 mg rivaroxaban dose in obese patients.
The data obtained from our trial support the up to now published results and also expand our understanding of the clinical pharmacology of rivaroxaban, specifically showing that the PK and PD properties remain unaltered after SG and RYGB.
This clinical trial is the first systematic investigation of rivaroxaban in bariatric surgery patients. It shows that there were no relevant alterations in the clinical pharmacology profile of rivaroxaban in the postoperative setting compared to results obtained prior to the surgical intervention. Single doses of 10 mg rivaroxaban showed an unremarkable safety profile without clinically relevant signs of bleeding after bariatric surgery and there was no thrombotic event observed during this clinical trial.
Limitations of this phase 1 clinical trial are the relatively small sample size and the single applications of rivaroxaban. However, it is important to note that rivaroxaban does not have significant accumulation after multiple doses, so that the single-dose profile is predictive of the multiple dose profile in patients without impaired renal function.
Another limitation is the short interval between the surgical intervention and the application of rivaroxaban. Although this takes into account the timeframe at interest for a prophylactic postoperative anticoagulation, it is not known whether PK parameters remain unchanged over the following period of weight loss and postsurgical functional adaptations of the gastrointestinal tract.
In conclusion, single doses of 10 mg rivaroxaban had a favourable PK, PD and safety profile in this limited bariatric surgery collective. The results of this study will help to design larger trials with clinical endpoints in this particular patient population with the final goal of safe and efficacious use of rivaroxaban in morbidly obese patients.
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